Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent® ): A Review in the Prevention of Influenza

Drugs
Yvette N Lamb

Abstract

Manufacturing influenza virus vaccines using a mammalian cell line rather than embryonated chicken eggs may carry certain advantages. A quadrivalent inactivated influenza virus vaccine produced using the Madin Darby canine kidney cell line has been approved in the EU (Flucelvax® Tetra) and USA (Flucelvax Quadrivalent®; QIVc hereafter) for the prevention of influenza in adults and children. The clinical development of QIVc has built upon that of a cell-based trivalent influenza virus vaccine (TIVc) manufactured using the same processes; the additional influenza B strain contained in QIVc reduces the risk of the strain in the vaccine not matching that in circulation. Pivotal phase III clinical trials in adult and paediatric participants have demonstrated the immunogenicity of QIVc to be noninferior to that of TIVc formulations against shared strains and superior against the influenza B strain absent from each TIVc formulation. Protective efficacy data for TIVc is considered foundational for QIVc and, in a phase III clinical trial, TIVc was effective in protecting adults against antigenically matched influenza strains. Large real-world studies from the 2017/2018 US influenza season further support the prophylactic effectiveness of...Continue Reading

References

Aug 14, 2009·The Journal of Infectious Diseases·Agnieszka Szymczakiewicz-MultanowskaAudino Podda
Jun 12, 2010·Biologicals : Journal of the International Association of Biological Standardization·David OnionsJens-Peter Gregersen
Sep 28, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sharon FreySandra Holmes
Nov 21, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Robyn HartvicksonAhmed Abdul Mateen
Jun 28, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Javier Diez-DomingoRicha Chandra
Dec 19, 2017·Lancet·A Danielle IulianoUNKNOWN Global Seasonal Influenza-associated Mortality Collaborator Network
Mar 31, 2018·Vaccines·Alfred T Harding, Nicholas S Heaton
Oct 11, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sigrid GoumaScott E Hensley

❮ Previous
Next ❯

Citations

Aug 24, 2019·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·Lisa A GrohskopfDaniel B Jernigan
May 12, 2020·Annual Review of Virology·Sigrid GoumaScott E Hensley
Mar 3, 2020·Frontiers in Microbiology·Olivia A Vogel, Balaji Manicassamy
May 14, 2020·F1000Research·Graham Pawelec, Janet McElhaney
Nov 12, 2020·Microorganisms·Steven RockmanIan G Barr

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00630331

Software Mentioned

QIVc

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.